US FDA approves oxymetazoline ophthalmic solution (Upneeq™) for the treatment of acquired blepharoptosis

This is the first medical treatment to be approved in the US for acquired blepharoptosis, or ptosis, a condition characterised by the abnormal drooping of the upper eyelid that can limit the field of vision. Approval was based on the results of two Phase III studies.


Biospace Inc.